Published in Proc Natl Acad Sci U S A on May 19, 2014
Recent Advances in Kawasaki Disease. Yonsei Med J (2016) 0.88
Kawasaki disease: insights into pathogenesis and approaches to treatment. Nat Rev Rheumatol (2015) 0.84
Metagenomic analysis of the airborne environment in urban spaces. Microb Ecol (2014) 0.83
Kawasaki disease: an epidemiological study in central Italy. Pediatr Rheumatol Online J (2016) 0.80
Kawasaki disease: a matter of innate immunity. Clin Exp Immunol (2016) 0.77
Computational modeling and engineering in pediatric and congenital heart disease. Curr Opin Pediatr (2015) 0.77
Use of corticosteroids during acute phase of Kawasaki disease. World J Clin Pediatr (2015) 0.77
Genetic epistasis between killer immunoglobulin-like receptors and human leukocyte antigens in Kawasaki disease susceptibility. Genes Immun (2015) 0.76
Ethnic Kawasaki Disease Risk Associated with Blood Mercury and Cadmium in U.S. Children. Int J Environ Res Public Health (2016) 0.76
Pathogenetic determinants in Kawasaki disease: the haematological point of view. J Cell Mol Med (2017) 0.75
Whole genome sequencing of an African American family highlights toll like receptor 6 variants in Kawasaki disease susceptibility. PLoS One (2017) 0.75
Adult Kawasaki disease in a European patient: a case report and review of the literature. J Med Case Rep (2015) 0.75
Soy isoflavone intake is associated with risk of Kawasaki disease. Nutr Res (2016) 0.75
Ambient Air Pollutant Exposures and Hospitalization for Kawasaki Disease in Taiwan: A Case-Crossover Study (2000-2010). Environ Health Perspect (2016) 0.75
Predicting the characteristics of the aetiological agent for Kawasaki disease from other paediatric infectious diseases in Japan. Epidemiol Infect (2015) 0.75
Epidemiology of Kawasaki disease in Italy: surveillance from national hospitalization records. Eur J Pediatr (2017) 0.75
A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics (1974) 9.97
Mycotoxins. Clin Microbiol Rev (2003) 5.59
Kawasaki syndrome. Lancet (2004) 5.09
Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect Dis (2009) 4.33
Refractory periods and climate forcing in cholera dynamics. Nature (2005) 3.98
Epidemiologic features of Kawasaki disease in Japan: results of the 2009-2010 nationwide survey. J Epidemiol (2012) 2.15
Kawasaki disease in families. Pediatrics (1989) 1.83
IgA plasma cell infiltration of proximal respiratory tract, pancreas, kidney, and coronary artery in acute Kawasaki disease. J Infect Dis (2000) 1.58
Searching for the cause of Kawasaki disease--cytoplasmic inclusion bodies provide new insight. Nat Rev Microbiol (2008) 1.56
Association of Kawasaki disease with tropospheric wind patterns. Sci Rep (2011) 1.38
An update on Kawasaki disease. Autoimmun Rev (2003) 1.08
Kawasaki disease: novel insights into etiology and genetic susceptibility. Annu Rev Med (2011) 1.08
Kawasaki disease may be a hyperimmune reaction of genetically susceptible children to variants of normal environmental flora. Med Hypotheses (2007) 1.04
Lethal and severe coronary arteritis in DBA/2 mice induced by fungal pathogen, CAWS, Candida albicans water-soluble fraction. Atherosclerosis (2005) 1.02
Maternal antibody against toxic shock syndrome toxin-1 may protect infants younger than 6 months of age from developing Kawasaki syndrome. J Infect Dis (2002) 0.96
Kawasaki disease: a maturational defect in immune responsiveness. J Infect Dis (1999) 0.90
Susceptibility loci to coronary arteritis in animal model of Kawasaki disease induced with Candida albicans -derived substances. Microbiol Immunol (2005) 0.88
Mizoribine provides effective treatment of sequential histological change of arteritis and reduction of inflammatory cytokines and chemokines in an animal model of Kawasaki disease. Pediatr Rheumatol Online J (2011) 0.85
A primer on the study of transitory dynamics in ecological series using the scale-dependent correlation analysis. Oecologia (2004) 0.84
Administration of human immunoglobulin suppresses development of murine systemic vasculitis induced with Candida albicans water-soluble fraction: an animal model of Kawasaki disease. Mod Rheumatol (2009) 0.83
Visualizing clinical evidence: citation networks for the incubation periods of respiratory viral infections. PLoS One (2011) 0.82
Finding Kawasaki disease. Ann Pediatr Cardiol (2012) 0.79
Etanercept suppresses arteritis in a murine model of kawasaki disease: a comparative study involving different biological agents. Int J Vasc Med (2013) 0.78